FUHUNG HANLIN AND SAUDI SVAX REACH STRATEGIC COOPERATION

Hong Kong, November 7, 2024/Media News/-- The 7th China International Import Expo (“Inbound Expo”) will be held in Shanghai from November 5 to 10, 2024. Resusciters will join forces with the Health Sector Member Companies to present a series of events with the theme of “Sharing Global Opportunities” on the theme of “On Time, Sharing Global Opportunities” Globally innovative products and themed events. On November 7, Fustar's innovative biopharmaceutical company Fuwang Hanlin entered into a strategic partnership with Al-TIRYAQ AL-KHALAWI Medical Company (“SVAX”), a subsidiary of Saudi Arabia's renowned Fakeeh family focused on healthcare.

Under the agreement, the two sides will establish joint ventures for commercialization and production in Saudi Arabia, and cooperate in the development and development of a range of products in the Central and North-East African Turkish region (MENAT), including Adami Singapore-Anti Handawan (HLX03), Beaver Mono Anti Hambert (HLX04) in the Middle East Turkey Region (MENAT). Local registration, production and commercialization. In addition, the first batch of projects under this cooperation framework also includes a joint investment in the development of Wang Han-Lin's self-developed Fabrizul monobiologous drug (HLX17), to jointly promote the product's worldwide registration.

Global layout, innovation-driven high quality offshore

With roots in China, growing globally, it has long maintained “globalization” and “innovation” as the two core growth engines, and has an industry layout in more than 35 countries and regions around the world. Pustar has been active in empowering and promoting its flagship enterprises to firmly implement their globalisation strategy. As an international innovative biopharmaceutical company, Fu Han-Lin continues to deepen its global presence, and with more than 20 international partners, actively drive the global listing process of products, now covering Asia, Europe, Latin America, North America and Oceania, the internationalization process has achieved a series of significant breakthroughs.

FUHUNG HANLIN NOTED THAT COOPERATION WITH SVAX IS AN IMPORTANT PART OF FUHUNG HANLIN'S GLOBALIZATION ROADMAP, WHICH WILL ACCELERATE THE COMPANY'S BUSINESS LAYOUT IN KEY MARKETS AND FURTHER ENHANCE THE INTERNATIONAL COMPETITIVENESS OF WANG HANLIN. The collaboration is expected to combine SVAX's deep resources and local experience in the MENAT region, with the global vision and innovation capabilities of Fuwang Han-lin, to accelerate the transformation of biomedical innovation outcomes and promote quality biopharmaceuticals for the benefit of more patients around the world.

SVAX pointed out that Fuwang Hanlin is known for its high quality and innovative biopharmaceuticals. By combining SVAX's knowledge and experience in pharmaceutical, marketing, sales, and local production, and Fuwang Hanlin's technology accumulation in biopharmaceutical development and global supply, the two sides are committed to bringing cutting-edge therapies to the MENAT region for the benefit of more patients. This collaboration will help increase the availability of highly effective medicines, in line with SVAX's vision of advancing the level of healthcare in Saudi Arabia and the wider region. SVAX WILL WORK HAND IN HAND WITH HANLIN FU HUNG TO DRIVE GROWTH, INNOVATION AND HEALTHCARE ACCESSIBILITY IN THE MENAT REGION.

FUHUNG HANLIN IS COMMITTED TO PROVIDING AFFORDABLE INNOVATIVE BIOPHARMACEUTICALS TO PATIENTS AROUND THE WORLD. ITS PRODUCTS COVER THE FIELDS OF TUMORS, AUTOIMMUNE DISEASES, EYE DISEASES, AND MORE. The company continuously improves the development and operational efficiency of the integrated R&D and sales platform. Through multi-dimensional product accessibility initiatives, the company drives the commercialization growth of its core products and achieves continuous high quality profits. Prospectively, the Company has a diversified, high-quality product pipeline covering more than 50 molecules, 6 products have been listed in China, 3 products have been approved on the international market, 24 indications have been approved, benefiting more than 0.67 million patients. Among them, Hengkuyu has been approved in 49 countries and regions around the world, making it the most domestically marketed anti-biosimilar drug in the country and region and benefiting more than 0.215 million patients with breast and stomach cancer.

The MENAT region is an important part of the global pharmaceutical market and the region's biopharmaceutical industry is experiencing rapid development thanks to the growing demand for local healthcare and the support of government policies. IN JUNE 2024, HANQU SUCCESSFULLY SHIPPED SAUDI ARABIA, BECOMING THE FIRST DOMESTIC ORDER ANTIBIOTIC TO LAND IN THE MIDDLE EAST MARKET. Fuhong Han-Lin's strong alliance with SVAX will not only facilitate bilateral pipeline layout and business layout, but also enhance pharmaceutical innovation capabilities in emerging markets.

A reinvigorated global operation focuses on the Middle East and opens up new growth prospects

Recently, Pustar has been operating in the Middle East region: In September, Lok Oil, a wholly-owned subsidiary of Hainan Mining, proposed a full tender offer for about RMB1.302 billion for Tethys Oil AB to acquire its oil field interests in several blocks of Oman.

IN JULY, HAINAN MINES SIGNED A MEMORANDUM OF UNDERSTANDING WITH AGILAN BROTHERS HOLDING GROUP TO DISCUSS THE FEASIBILITY OF BUILDING LITHIUM SALT PROJECTS IN SAUDI ARABIA AND ESTABLISH AN INDUSTRY FUND BASED ON UPSTREAM LITHIUM RESOURCES, LOCAL MINERAL EXPLORATION AND GLOBAL NEW ENERGY METAL MINERALS AND TECHNOLOGY INVESTMENTS.

In the same month, FFT, the world's leading supplier of flexible automation production line solutions under Fustar, signed a joint venture agreement with Khaled Juffali Holding Company (KJC), a Saudi family-owned enterprise to establish a business technology entity in Saudi Arabia and partner with FFT shareholder Yao Technology in Shanghai to provide automation to the Saudi electric vehicle industry Optimized production line solutions. The joint venture has acquired the first project in the Saudi automotive industry.

In addition, FFT plans to expand into other industries in Saudi Arabia that require automation and robot assembly. With extensive experience in automation and robotics, FFT hopes to set new standards in the industry in Saudi Arabia.

In May, Club Med, the world's leading travel resort brand, announced its entry into the Middle East market with the launch of its first project in Oman — Club Med Musandam. The project marks Club Med's deep partnership with Oman's Royal Court Affairs and Omran Group, which will open in early 2026 and open in 2028.

Under the Vision 2023 guidance, Saudi Arabia is rapidly becoming a hub for sports, especially e-sports. At the recent eSports World Cup in Riyadh, the Wolves esports club under the banner of Resurrection Sports clinched two titles in “Game of Genting” and “Glory of Kings”. Further cooperation between the two sides has become a trend with the continued commitment of Saudi towards esports and the excellent performance of Star Sports in football and eSports.

With its vitality and strong economic growth, the Middle East is becoming a key frontier in the resurgent global landscape. The achievement of multiple industries and projects in such a short period of time fully demonstrates Resurrection's high efficiency and commitment to the Middle East market.

GUO GUANGCHANG, CHAIRMAN OF FUSTAR INTERNATIONAL, SAID, “FUXING LOOKS FORWARD TO BUILDING LONG-TERM, STABLE STRATEGIC COOPERATION WITH MORE MIDDLE EAST PARTNERS. As a company with global operations capabilities and a deep focus on the Chinese market, I believe ResusStar is the best strategic partner. With our global operating capabilities and extensive experience, ResusStar is able to work with partners in the Middle East to achieve continuous value growth to create a new win-win ecosystem.”